Loading page…

Report overview

The report describes a resilient 2020 for the LEO Group, despite COVID-19 disruption. The company awarded 25 grants totaling DKK 72 million and LEO Pharma launched a 2030 strategy focused on global leadership in medical dermatology. LEO Pharma also reported positive phase 3 results for tralokinumab and launched its first science-based climate target, alongside completing a Scope 1, 2 and 3 carbon footprint.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2020
Period: 1 January 2020 – 31 December 2020
Publication date: 24 March 2021
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Assurance

Level
Standard
Scope
Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board
Women in management

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services